Ignite Creation Date:
2024-05-06 @ 3:30 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04656249
Status:
COMPLETED
Last Update Posted:
2021-06-04
First Post:
2020-11-30
Brief Title:
Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
The Efficacy and Safety of Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LENABC
Brief Summary:
This is a single center nonrandom open-label study aiming to evluate the efficacy and safety of lenvatinib for patients with pretreated advanced biliary tract cancer
Detailed Description:
Lenvatinib targets VEGFR1 2 and 3 PDGFRα Fibroblast growth factor receptor FGFR and the KIT and RET tyrosine kinases and was initially developed for use in various tumor types This is a single-center non-random open-label study in participants with unresectable BTC and disease progression or failure following at least one chemotherapy regimen This study contains three procedures a pre-treatment procedure that will last within 21 days a treatment procedure that will consist of study treatment cycles and tumor assessment conducted every 6-8 weeks and a follow-up procedure that will begin immediately after the off-treatment visit and will continue as long as the participant is alive unless the participant withdraws consent or until the terminal of the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None